NCT05544019 2026-02-13Study of SGR-1505 in Mature B-Cell NeoplasmsSchrödinger, Inc.Phase 1 Recruiting98 enrolled
NCT06544265 2025-12-18SynKIR-310 for Relapsed/Refractory B-NHLVerismo TherapeuticsPhase 1 Recruiting18 enrolled
NCT02924402 2024-11-13Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesXencor, Inc.Phase 1 Completed154 enrolled
NCT04637009 2024-08-02A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsAstex Pharmaceuticals, Inc.Phase 1 Terminated20 enrolled
NCT05328102 2024-04-30Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)Xencor, Inc.Phase 2 Terminated3 enrolled 6 charts
NCT01236352 2019-07-31Multiple Ascending Dose of BMS-911543Bristol-Myers SquibbPhase 1/2 Terminated98 enrolled 20 charts
NCT00884546 2016-09-30Multiple Ascending Dose (MAD) Combination in Subjects With Multiple MyelomaBristol-Myers SquibbPhase 1 Completed27 enrolled
NCT01046864 2014-09-16Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)Bristol-Myers SquibbPhase 1 Completed49 enrolled